Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

43.55B

Market cap43.55B

Price-Earnings ratio

141.10

Price-Earnings ratio141.10

Dividend yield

—

Dividend yield—

Average volume

1.28M

Average volume1.28M

High today

$332.81

High today$332.81

Low today

$325.47

Low today$325.47

Open price

$328.99

Open price$328.99

Volume

1.11M

Volume1.11M

52 Week high

$495.55

52 Week high$495.55

52 Week low

$205.87

52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $328.21, with a market capitalization of 43.55B. The stock trades at a price-to-earnings (P/E) ratio of 141.10.

On 2026-03-27, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $325.47 to $332.81. With shares now at $328.21, the stock is trading +0.8% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 1.11M, compared to an average daily volume of 1.28M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

TipRanks 2d

Alnylam Buy Rating Backed by Expanding ATTR-CM Opportunity, Durable Amvuttra Leadership, and Long-Term Growth Visibility

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Alnylam Pharma, with a price target of $549.00. Salveen Richter h...

TipRanks 2d

Alnylam Pharmaceuticals: Underpenetrated TTR Market and Strong Commercial Execution Support Buy Rating

Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma, retaining the price target of $510.00. Joseph Stringer has given his Buy rating d...

Simply Wall St 2d

Assessing Alnylam Pharmaceuticals Valuation After Recent Share Price Weakness

Advertisement Context for Alnylam Pharmaceuticals after recent price moves Alnylam Pharmaceuticals (ALNY) has drawn investor attention after mixed recent retu...

Analyst ratings

71%

of 28 ratings

Buy

71.4%

Hold

28.6%

Sell

More ALNY News

TipRanks 3d

Alnylam announces set of efforts to improve care for patients with ATTR-CM

Alnylam (ALNY) Pharmaceuticals announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with t...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Eli Lilly

Vertex Pharmaceuticals

Broadcom

AMD

Netflix

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.